Literature DB >> 24698169

The relationship of neuroimaging findings and neuropsychiatric comorbidities in children with tuberous sclerosis complex.

Cheng-Hsien Huang1, Steven Shinn-Forng Peng2, Wen-Chin Weng3, Yi-Ning Su4, Wang-Tso Lee5.   

Abstract

BACKGROUND/
PURPOSE: To clarify the relationship between neuroimaging findings, neuropsychiatric comorbidities, and epilepsy in patients with tuberous sclerosis complex (TSC) in Taiwan.
METHODS: Medical records from 32 patients with TSC were retrospectively reviewed, including mutational analysis, neuroimaging findings, electroencephalogram findings, and neuropsychiatric comorbidities.
RESULTS: Of these patients, six (18.75%) were diagnosed to have autism spectrum disorders (ASD), and 10 (31.25%) were diagnosed to have attention-deficit-hyperactivity disorder. In the latter patients, there were no differences in the regional distribution of tuber burden. In addition to a high prevalence of cystic-like tubers, tubers in insular and temporal areas were associated with ASD. Nonsense mutations in the TSC2 gene group had a correlation with autistic behavior. In 26 (81.25%) patients with a history of epilepsy, infantile spasms and partial seizures were the predominant type of epilepsy. Most of them developed seizures prior to age 1 year.
CONCLUSION: ASD is a common comorbidity in TSC. Cortical tubers in the temporal lobe and insular area were associated with ASD. The presence of cystic-like tubers on magnetic resonance imaging may also offer a structural marker for ASD in TSC.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  attention-deficit–hyperactivity disorder; autism spectrum disorder; seizure; tuberous sclerosis complex

Mesh:

Substances:

Year:  2014        PMID: 24698169     DOI: 10.1016/j.jfma.2014.02.008

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  7 in total

1.  Re: Coexistence of Autism Spectrum Disorders Among Three Children with Tuberous Sclerosis Complex: Case reports and review of literature.

Authors:  Mahmood D Al-Mendalawi
Journal:  Sultan Qaboos Univ Med J       Date:  2017-03-30

2.  [Two novel TSC2 frameshift mutations in tuberous sclerosis complex].

Authors:  Yu-Chun Pan; Wei-Qing Wu; Jian-Sheng Xie; Cai-Qun Luo; Ying Hao
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-03

Review 3.  A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND).

Authors:  Petrus J de Vries; Lucy Wilde; Magdalena C de Vries; Romina Moavero; Deborah A Pearson; Paolo Curatolo
Journal:  Am J Med Genet C Semin Med Genet       Date:  2018-08-16       Impact factor: 3.908

4.  Profile of Autism Spectrum Disorder in Tuberous Sclerosis Complex: Results from a Longitudinal, Prospective, Multisite Study.

Authors:  Jamie K Capal; Marian E Williams; Deborah A Pearson; Robin Kissinger; Paul S Horn; Donna Murray; Kristn Currans; Bridget Kent; Martina Bebin; Hope Northrup; Joyce Y Wu; Mustafa Sahin; Darcy A Krueger
Journal:  Ann Neurol       Date:  2021-10-29       Impact factor: 10.422

5.  Cortical dysplasia and autistic trait severity in children with Tuberous Sclerosis Complex: a clinical epidemiological study.

Authors:  Sabine E Mous; Iris E Overwater; Rita Vidal Gato; Jorieke Duvekot; Leontine W Ten Hoopen; Maarten H Lequin; Marie-Claire Y de Wit; Gwendolyn C Dieleman
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-10-23       Impact factor: 4.785

6.  Two novel TSC2 mutations in pediatric patients with tuberous sclerosis complex: Case report.

Authors:  Shan Gao; Zhiling Wang; Yongmei Xie
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

7.  Autism spectrum disorder in tuberous sclerosis complex: searching for risk markers.

Authors:  Aglaia Vignoli; Francesca La Briola; Angela Peron; Katherine Turner; Chiara Vannicola; Monica Saccani; Elisabetta Magnaghi; Giulia Federica Scornavacca; Maria Paola Canevini
Journal:  Orphanet J Rare Dis       Date:  2015-12-02       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.